Regenxbio Stock Price, News & Analysis

REGENXBIO announced positive interim data from Phase II trials of RGX-314 for treating wet AMD and diabetic retinopathy. The AAVIATE trial showed RGX-314 was well tolerated among 50 patients, with no serious adverse events. In Cohort 2, a 71.8% reduction in anti-VEGF treatment burden was observed, with 40% of patients injection-free. Cohort 1 of the ALTITUDE trial reported stable visual acuity at three months. These results were presented at the AAO 2021 Annual Meeting, highlighting RGX-314's potential in retinal disease management.

REGENXBIO (Nasdaq: RGNX) has finalized a collaboration and license agreement with AbbVie for the gene therapy RGX-314, targeting wet AMD and diabetic retinopathy. The deal includes a $370 million upfront payment and potential earnings of up to $1.38 billion based on future milestones. REGENXBIO will manage ongoing trials, while AbbVie will lead global clinical development and commercialization. Both companies will share profits from U.S. sales equally, with tiered royalties on international sales. RGX-314 aims to inhibit VEGF, which contributes to retinal fluid accumulation.

REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in two upcoming virtual investor conferences. The Barclays Gene Editing & Gene Therapy Summit is set for November 15, 2021, at 1:30 p.m. ET. Additionally, the Piper Sandler 33rd Annual Virtual Healthcare Conference will take place on December 2, 2021, with a recorded fireside chat available starting November 22, 2021, at 10:00 a.m. ET. A live webcast and recorded presentations can be accessed via REGENXBIO's website for 30 days post-event.

REGENXBIO Inc. (Nasdaq: RGNX) announced that data from its RGX-314 clinical trials will be presented at the American Academy of Ophthalmology 2021 Annual Meeting in New Orleans, LA, from November 12-15, 2021. RGX-314, a potential one-time gene therapy targeting wet age-related macular degeneration and diabetic retinopathy, will be showcased in an oral presentation by Dr. Robert L. Avery on November 12. The therapy utilizes the NAV AAV8 vector to inhibit VEGF, potentially preventing fluid accumulation in the retina.

REGENXBIO and AbbVie announced a strategic collaboration to develop RGX-314, focusing on wet AMD and diabetic retinopathy, with REGENXBIO receiving a $370 million upfront payment. The partnership aims to leverage both companies' expertise for potential milestone payments totaling $1.38 billion. Positive Phase II trial data for RGX-314 showed stable visual acuity and reduced treatment burden. Financially, REGENXBIO reported $30.8 million in Q3 revenues, down from $98.9 million the same period in 2020, and a net loss of $58.4 million. Cash reserves were $533.5 million as of September 30, 2021.

REGENXBIO Inc. (Nasdaq: RGNX) announced a conference call scheduled for November 2, 2021, at 4:30 p.m. ET. The call will cover the company's financial results for the quarter ended September 30, 2021, and recent operational highlights. Investors can access the call via phone or a webcast on the REGENXBIO website. The company is focused on gene therapy through its NAV^® Technology Platform, which includes over 100 exclusive AAV vectors aimed at various therapeutic areas.

REGENXBIO announced positive interim data from the Phase II ALTITUDE trial of RGX-314, a gene therapy for diabetic retinopathy (DR). In Cohort 1, 33% of patients showed a two-step improvement in DR severity after three months, compared to none in the control group. The treatment was well-tolerated with no serious drug-related adverse events. Cohorts 2 and 3 are ongoing at a higher dose of 5x10¹¹ GC/eye. This therapy could significantly benefit the approximately eight million people affected by DR in the U.S.

REGENXBIO (Nasdaq: RGNX) announced positive initial data from the Phase II AAVIATE trial of RGX-314 for wet AMD treatment via suprachoroidal delivery. In Cohort 1, 14 patients showed stable visual acuity and retinal thickness at six months, with a 75.9% reduction in anti-VEGF injections. No drug-related serious adverse events were reported among 50 patients in Cohorts 1-3. The trial is expanding to include a third dose level of RGX-314. A conference call featuring key opinion leaders will provide further insights.

REGENXBIO announced that data from its RGX-314 clinical trials will be presented at the American Society of Retina Specialists Annual Meeting in San Antonio, TX, from October 8-12, 2021. The presentations will focus on interim results from the Phase II ALTITUDE trial, which evaluates RGX-314 for diabetic retinopathy. Key presentations include early results from Cohort 1 on October 9 and additional studies on neovascular AMD on October 11.